MAH Requirements in Saudi Arabia: Who Can Hold an SFDA Marketing Authorization?

The MAH is the legal entity in whose name the SFDA marketing authorization is issued. It carries the regulatory responsibility for the product throughout its life on the Saudi market: the accuracy of the registered dossier, the quality of every batch released, safety monitoring and adverse event reporting, and the timely filing of variations and renewals.

The MAH does not have to manufacture every step of the product itself, but it must be the entity that owns and controls the product — which is exactly where many registration plans go wrong.

In practice, yes. For the SFDA to recognize a company as MAH, it expects the company to own — or be corporately linked to — at least one manufacturing site registered with the SFDA. The rule keeps the marketing authorization in the hands of the real product owner rather than a commercial intermediary: a company whose only connection to the product is a purchase or distribution agreement does not qualify.

This matters most for virtual companies and license holders. Contract manufacturing is common and accepted, but the application structure must still show the ownership link between the MAH and a registered site. A trading company that cannot show that link can act as the local agent for the registration — it cannot be the MAH.

A foreign MAH cannot file or hold a registration directly. It must appoint a locally licensed agent through which the SDR application is submitted, with the relationship registered at the Ministry of Commerce and evidenced by an Agency Registration Certificate in the registration file.

Beyond representation, the MAH must maintain a local pharmacovigilance system with a Qualified Person for Pharmacovigilance (QPPV) based in Saudi Arabia, keep bilingual Arabic-English labeling compliant, and ensure every manufacturing site in the supply chain holds SFDA GMP clearance.

The three roles are frequently confused. The MAH owns the product and the authorization. The local agent is the Saudi-licensed entity that submits the application, receives SFDA correspondence, and represents the MAH in the Kingdom under a registered agency agreement. A scientific office is a foreign company's own licensed presence in Saudi Arabia, used for scientific promotion and pharmacovigilance activities in its own name.

Choosing the structure early matters: the names on the agency agreement, Commercial Registration, SFDA licenses, and the SDR application must align exactly, and restructuring mid-review is one of the more expensive ways to lose months.

Marketing authorizations move — through acquisitions, licensing deals, or changes of agent — and each move is a regulated procedure, not a paperwork swap. Transfers and agent changes are handled through the SFDA's variation procedures, with updated agency documentation, and should be planned around renewal timing so the authorization never lapses mid-transfer.

The pathway and obligations that apply are set out in the SFDA Regulatory Framework for Drug Approval, which defines applicant responsibilities across submission, assessment, and the post-approval lifecycle.

MRG acts as licensed local agent for foreign MAHs — holding SFDA Consultation Office license CO-2023-FO-0022 — and manages the full structure around the authorization: agency agreement setup and MOC registration, SFDA drug registration through the SDR platform, QPPV and pharmacovigilance services, and lifecycle management of variations, renewals, and transfers through our pharmaceutical regulatory services.

If you are structuring a Saudi registration and are unsure who should hold the authorization, ask us before you file — the MAH decision is the hardest one to change later.